Summit Therapeutics (SMMT) closed at $11.82 on November 16, 2026, down 16.5% from the previous close, on volume of 22,045,780 shares (30-day average 4,771,908).
Data as of November 16, 2026.
16-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 16, 2026 | Call Spread | 15-Jan-2715 : 25 C | 20,442 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
Stifel Nicolaus Sticks to Its Buy Rating for Summit Therapeutics (SMMT)
TipRanks (Mon, 16-Nov 9:45 AM ET)
FDA declines approval of Summit’s lung cancer treatment, SMMT drops 13% in premarket
Seeking Alpha News (Mon, 16-Nov 8:44 AM ET)
TipRanks (Mon, 16-Nov 8:10 AM ET)
Summit Therapeutics (SMMT) Gets a Hold from Piper Sandler
TipRanks (Mon, 16-Nov 7:45 AM ET)
Why Is Summit Therapeutics Stock (SMMT) Plunging in Premarket Today, November 16?
TipRanks (Mon, 16-Nov 7:03 AM ET)
Summit Therapeutics Receives FDA Complete Response Letter for Ivonescimab
TipRanks (Mon, 16-Nov 7:02 AM ET)
TipRanks (Mon, 16-Nov 6:30 AM ET)
TipRanks (Mon, 16-Nov 5:50 AM ET)
Summit Therapeutics (SMMT) Gets a Hold from Barclays
TipRanks (Mon, 16-Nov 4:26 AM ET)
FDA declines approval of Summit’s lung cancer treatment
Seeking Alpha News (Sun, 15-Nov 2:06 PM ET)
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Summit Therapeutics trades on the NASDAQ stock market under the symbol SMMT.
As of November 16, 2026, SMMT stock price declined to $11.82 with 22,045,780 million shares trading.
SMMT has a beta of 2.17, meaning it tends to be more sensitive to market movements. SMMT has a correlation of 0.13 to the broad based SPY ETF.
SMMT has a market cap of $9.43 billion. This is considered a Mid Cap stock.
Last quarter Summit Therapeutics reported $0 in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-53,790 and exceeded earnings estimates by $.02.
In the last 3 years, SMMT traded as high as $36.91 and as low as $1.88.
The top ETF exchange traded funds that SMMT belongs to (by Net Assets): VTI, VB, XBI, VBR, VXF.
SMMT has underperformed the market in the last year with a price return of -34.4% while the SPY ETF gained +11.3%. SMMT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.5% and -20.1%, respectively, while the SPY returned -4.4% and -1.6%, respectively.
SMMT support price is $13.33 and resistance is $14.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SMMT shares will trade within this expected range on the day.